Biomarker Testing Services Compared: What They Actually Test

What This Category of Service Generally Offers

Direct-to-consumer biomarker platforms typically combine three things: (1) a broad lab panel — often 50 to 100+ individual biomarkers covering metabolic, hormonal, inflammatory, cardiovascular, and nutrient markers in a single draw; (2) a consumer-facing app or dashboard that reports results against optimal (not just "normal") reference ranges; and (3) some form of physician or clinician review, typically required to legally order lab work in most US states, though the depth of that review varies significantly by company — from a brief sign-off to an actual consultation.

This is a different service model than a traditional lab (like Quest or Labcorp), which processes orders from a treating physician but doesn't typically build a consumer-facing interpretation layer, and different from a wearable device (like Whoop or Oura), which tracks continuous physiological signals (heart rate, HRV, sleep stages) rather than blood biomarkers. Some platforms in this space are beginning to combine both — blood panels plus wearable data — into a single dashboard.

What Actually Varies Between Providers

Because this is a fast-moving, competitive category, specific panel sizes, prices, and included markers change frequently — anything printed here as a fixed number would likely be out of date within months. Instead, here's what's worth comparing directly on each company's own site before choosing one:

• Panel breadth and specific markers included. Do they test fasting insulin and HOMA-IR components (see our fasting insulin guide), a full thyroid panel (see our thyroid panel guide), and sex hormones (see free testosterone and SHBG), or a narrower set?
• Reference ranges used. Some platforms report against "optimal" ranges that are narrower than the standard lab-normal range, which can flag values a conventional doctor would consider unremarkable — useful for some people, alarming or confusing for others without context.
• Clinician involvement. Whether a physician reviews and can act on abnormal results (e.g., order follow-up testing or a prescription) or the service is purely informational.
• Retest cadence and cost model. Subscription vs. one-time panel, and how often retesting is included or discounted — relevant given that most biomarkers are only useful tracked over time, not as a single snapshot.
• Whether it integrates with wearables. Some platforms pair blood biomarkers with continuous data from devices like Whoop or Oura (see our overview of HRV for what that continuous data measures) rather than blood work alone.

How This Differs From a Doctor's Panel

The core tradeoff is breadth and proactivity versus insurance coverage and continuity of care. Direct-to-consumer platforms generally aren't billed through insurance (most are cash-pay), and they aren't a substitute for a primary care relationship — abnormal results still typically need follow-up with a physician who can order additional testing, prescribe treatment, or coordinate specialist referrals. What they add is testing breadth most standard checkups don't include by default, at the cost of paying out of pocket and doing more of the interpretation legwork yourself (even with the platform's own dashboard).

For a broader look at which specific markers are worth prioritizing regardless of which service (or your own doctor) orders them, see our biomarkers overview, which covers the priority markers this site recommends tracking and the testing strategy behind them.